U.S. Pricing Law Cut European Drug Launches by 35%
Pharmaceutical firms are delaying new product rollouts to avoid triggering lower global price benchmarks.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Should governments prioritize lower drug prices even if it risks delaying access to new treatments?
As of March 2026, a 35% drop in new drug launches across Europe followed the U.S. government's enactment of a most-favored-nation pricing policy in May 2025. The shift, which links Medicare reimbursements to the lowest global prices, has altered how manufacturers prioritize international market entries.
Why it matters
Companies are deprioritizing smaller markets to protect high-margin U.S. revenues from downward price benchmarking. This strategic recalibration has led to supply gaps for innovative therapies in regions like Morocco that rely on external innovation pipelines.
A study of 195 patented drugs accounting for $87.9 billion in U.S. annual spending tracked a 35% decline in European launches as of March 2026. The shift persists despite varied regulatory landscapes, including Moroccan markets which currently lack mandates for timely drug introductions.
The players
Amine Tehraoui
The Minister of Health and Social Protection in Morocco who is managing the domestic fallout of medication shortages.
Naïma El Fathaoui
A Representative who submitted a formal inquiry regarding the impact of drug availability on chronic disease treatments.
The details
Pharmaceutical manufacturers are adjusting commercial schedules to prevent low prices in secondary markets from serving as the floor for U.S. Medicare reimbursements. By delaying or withholding releases in Europe, firms avoid pricing data that would otherwise force domestic U.S. price reductions. This has resulted in specific withdrawals, such as a severe hypercholesterolemia treatment removed from European shelves in February 2026.
Timeline
May 2025: The U.S. signed the most-favored-nation pricing policy into law.
February 2026: A hypercholesterolemia treatment was withdrawn from European markets.
March 2026: New drug launches in Europe dropped by 35%.
June 1, 2026: Minister Amine Tehraoui addressed medication shortages in the House of Representatives.
Mid-June 2026: European ministers mandated an impact assessment of the U.S. policy.
Market Landscape
The 35% decline in European product launches is a direct response to the U.S. most-favored-nation pricing policy enacted in 2025. This trend marks a shift away from traditional global rollout strategies as manufacturers now prioritize U.S. regulatory pricing floors over broader international reach.
Operators in the healthcare sector should prepare for increased volatility in product availability and potential supply chain disruptions. Review commercial agreements and import dependencies, as firms are increasingly prioritizing market access based on global pricing benchmarks.
The takeaway
The implementation of U.S. pricing mandates has fundamentally altered global pharmaceutical distribution strategies, favoring U.S. margins over European market entry. Operators should monitor local regulatory developments and supply chain contingencies for critical drugs as manufacturers continue to adjust global launch schedules.
Further reading
For more context on international pharmaceutical supply dynamics, see the Healthcare section.
Source note: This article includes information reported by Telquel.
Live Poll
Should governments prioritize lower drug prices even if it risks delaying access to new treatments?
